Home › Funds › Grantham, Mayo, Van Otterloo & Co. LLC › GSK

Grantham, Mayo, Van Otterloo & Co. LLC position in GSK

GSK PLC · Health Care

Grantham, Mayo, Van Otterloo & Co. LLC reported holding 3,917,951 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$188.7M, representing 0.41% of its reported portfolio and ranking #40 among its reported holdings. Grantham, Mayo, Van Otterloo & Co. LLC has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.92M sh
Reported value held$188.73M
Portfolio Weight0.41%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Grantham, Mayo, Van Otterloo & Co. LLC's GSK position evolved

Grantham, Mayo, Van Otterloo & Co. LLC first disclosed a stake in GSK in Q3 2023 at 1,266,444 shares (US$45.9M). The position peaked in Q1 2026 at 3,522,566 shares, worth US$194.4M. Across 13 filings, Grantham, Mayo, Van Otterloo & Co. LLC increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,917,951 shares valued at US$188.7M — an increase of 318,430 shares quarter over quarter.. Notable position changes include a 108% increase in Q2 2024 (shares rose 6% over the following quarter), a 48% trim in Q1 2025 (shares were roughly flat over the following quarter), a 36% increase in Q4 2025 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.27M $45.91M New
Q4 2023 1.68M $62.22M Add
Q1 2024 1.51M $64.69M Reduce
Q2 2024 3.15M $121.10M Add
Q3 2024 3.71M $151.54M Add
Q4 2024 4.15M $140.48M Add
Q1 2025 2.14M $82.93M Reduce
Q2 2025 2.60M $99.90M Add
Q3 2025 2.57M $111.01M Reduce
Q4 2025 3.49M $171.12M Add
Q1 2026 3.52M $194.41M Add
Q2 2026 3.60M $188.69M Add
Q3 2026 3.92M $188.73M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GSK and 13F data

GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GSK

All GSK fund holders →

FAQ

How long has Grantham, Mayo, Van Otterloo & Co. LLC held GSK?

Grantham, Mayo, Van Otterloo & Co. LLC has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Grantham, Mayo, Van Otterloo & Co. LLC's current position in GSK?

As of Q3 2026, Grantham, Mayo, Van Otterloo & Co. LLC holds 3.92M shares of GSK (GSK PLC), valued at $188.73M, representing 0.41% of its reported portfolio and ranking #40.

Has Grantham, Mayo, Van Otterloo & Co. LLC been buying or selling GSK?

In the latest 13F filing (Q3 2026), Grantham, Mayo, Van Otterloo & Co. LLC increased its position in GSK. The position peaked in Q1 2026 at 3.52M shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 19 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.